CD8A and neoplasm: Since IL-15 activates anti-tumor effectors such as NK cells, γδ T lymphocytes, and memory phenotype CD8+ T cells and exerts more long-lasting antitumor effects, it might be especially suitable for immunotherapy of NMIBC.